Novartis has a sound strategy to navigate a world with a growing, aging population and continuously evolving healthcare needs. Our mission and vision complement our strategy, and together they support the creation of value over the long term for our company, our shareholders and society. Read more about our mission and vision.
Our strategy is to use science-based innovation to deliver better outcomes for patients in growing areas of healthcare. We maintain strong investment in research and development (R&D) focused on areas of unmet medical need. We seek to develop medicines and products that can produce positive real-world outcomes for patients and healthcare providers. We aim to develop innovative products in growing areas of healthcare where we can make a real difference. At the same time, we are expanding our presence in the emerging markets of Asia, Africa and Latin America, where populations are growing fastest and where demand for access to high-quality medicines and healthcare is also likely to continue to increase.
Expanding access and doing business responsibly
We focus our corporate responsibility (CR) work in two areas: expanding access to healthcare and doing business responsibly. This combination of responsible business and making medicines accessible are important elements supporting our company mission, vision and strategy.
To help us find ways to improve access to our treatments for as many people as possible, we offer an array of approaches, including innovative, sustainable business models; equitable commercial models; zero-profit models; patient assistance programs and philanthropic efforts.
To help us become a trusted leader in changing the practice of medicine, we are taking steps to ensure our standards align with society’s increasingly high expectations by strengthening our compliance function, continuing to educate our associates, and changing how we interact with customers. At the same time, we are working to increase our environmental sustainability, reducing our footprint in our day-to-day operations.
Corporate responsibility is endorsed and ingrained at the highest level in the company. The Governance, Nomination and Corporate Responsibilities Committee (GNCRC) of the Board of Directors of Novartis AG specifically oversees the company’s strategy and governance on CR topics that may affect the company’s business and reputation. The engagement and dedication of our associates help bring all of these initiatives to life.
We are committed to transparent reporting – a central part of our UN Global Compact obligations. Our Annual Report serves as our primary reporting mechanism for corporate responsibility, and we have published a combined financial and CR report since 2000.
Our Corporate Responsibility Performance Report consolidates the company’s CR reporting and details our progress against our targets. It is based on the Global Reporting Initiative G4 guidelines, with disclosure at “comprehensive” level.